Welcome

...to Biotech Outsourcing Strategies Basel 2022

Launched in 2006 by Bio2Business Ltd, the Biotech Outsourcing Strategies Events bring together stakeholders in R&D outsourcing to share experience, build existing outsourcing partnerships and forge new buyer/supplier business relationships. The established BOS Formula is built on 4 key pillars; Exhibition showcasing international CROs and CMOs; High Quality Content (delivered through the multi-stream programme); 1-to-1 Partnering; Informal Networking (BOS Events are known for being friendly, intimate events, which create the perfect conditions for networking!).

Since 2016 we are pleased to call Basel our home of our summer event. Located in the heart of Europe, Basel is a unique Life Science Ecosystem which we are proud to support. BOS Basel 2022 will cover Discovery Outsourcing, Small Molecule CMC Outsourcing and Biologics CMC Outsourcing.

Covid Policy: click here to read the latest on Covid guidelines.

Badge QR Code: A QR code will be sent to you on Thursday 4th June and a reminder email sent with the same QR Code on Tuesday 7th June. Please have this QR code ready to present when you arrive at the venue so that your badge can be printed without delay. Contact Bio2Business if you have not received your badge given the schedule outlined herein.

Book your accommodation at BOS Basel 2022 by clicking here.

View Exhibition Floor plan

Important checklist for Sponsors

Important checklist for Exhibition Sponsors

Featured Speaker (BOS Basel 2022)

Outsourcing Antibody and Antibody-Drug-Conjugates Development and Manufacturing: When, Who, and How?

Dr Ulrich Rümenapp, Head of Launch Preparation (Biotech Strategy), Bayer Schering Pharma AG

ABSTRACT: Outsourcing partnerships for CMC development and manufacturing of biologics are of strategic importance for many companies esp. with innovative pipelines and employing new technologies. Antibody-drug conjugates (ADCs), linking small molecule highly potent drugs to antibodies for efficacy and targeting, offer new treatment options esp. in oncology, while the complexity of ADCs makes their CMC development and manufacturing challenging. Especially in determining its clinical as well as commercial manufacturing set-up, companies must consider what best suits their needs and decide between building... Click here to Read More

Featured Company (BOS Basel 2022)

Symeres
Symeres is the leading mid-sized Trans Atlantic CRO/CDMO for your drug discovery and development needs. With over 600 scientists at seven locations, we offer best-in-class solutions for drug discovery and drug development for small molecules and beyond. Our services span from early-stage hit finding...
View profile